aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
Abstract Objective Autologous hematopoietic stem cell transplantation (aHSCT) is increasingly recognized as a potential therapy for patients with highly active multiple sclerosis (MS). This study aims to assess outcome differences in disease activity in MS patients treated either with aHSCT or alemt...
Main Authors: | Vivien Häußler, Friederike Ufer, Jana Pöttgen, Christine Wolschke, Manuel A. Friese, Nicolaus Kröger, Christoph Heesen, Jan‐Patrick Stellmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Annals of Clinical and Translational Neurology |
Online Access: | https://doi.org/10.1002/acn3.51366 |
Similar Items
-
Smartphone Accelerometry: A Smart and Reliable Measurement of Real-Life Physical Activity in Multiple Sclerosis and Healthy Individuals
by: Yuyang Zhai, et al.
Published: (2020-08-01) -
Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis
by: Mohammadi R, et al.
Published: (2021-03-01) -
The Predictive Role of NEDA in the Long-Term Course of Multiple Sclerosis
by: Özgü Kizek
Published: (2017-03-01) -
Thingifying Neda: The Construction of Commemorative and Affective Thingifications of Neda Agda Soltan
by: Carsten Stage
Published: (2011-10-01) -
Thingifying Neda: The Construction of Commemorative and Affective Thingifications of Neda Agda Soltan
by: Carsten Stage
Published: (2011-10-01)